2023
Leveraging collaborative learning for improved heart failure care: insights from Argentina
Raja M, Ahmad T, Samad Z. Leveraging collaborative learning for improved heart failure care: insights from Argentina. International Journal For Quality In Health Care 2023, 35: mzad067. PMID: 37616486, DOI: 10.1093/intqhc/mzad067.Peer-Reviewed Original ResearchElectronic Health Record Embedded Strategies for Improving Care of Patients With Heart Failure
Fuery M, Kadhim B, Samsky M, Freeman J, Clark K, Desai N, Wilson F, Ahmed T, Ahmad T. Electronic Health Record Embedded Strategies for Improving Care of Patients With Heart Failure. Current Heart Failure Reports 2023, 20: 280-286. PMID: 37552356, DOI: 10.1007/s11897-023-00614-0.Peer-Reviewed Original ResearchConceptsHeart failure patientsFailure patientsElectronic health recordsEHR alertClinical trialsRandomized clinical trialsCare of patientsQuality of careHeart failureClinician satisfactionRandomized fashionRecent FindingsTherePatientsUnmet needPatient careClinical decisionEvidence-based decisionsFuture interventionsCareHealth recordsTrialsCliniciansInterventionFindingsThereRisk Prediction for Heart Failure Patients Admitted to the Intensive Care Unit Insights From REVeAL-HF
O’Connor K, Yamamoto Y, Sen S, Samsky M, Wilson F, Desai N, Ahmad T, Fuery M. Risk Prediction for Heart Failure Patients Admitted to the Intensive Care Unit Insights From REVeAL-HF. JACC Heart Failure 2023, 11: 727-728. PMID: 37052546, DOI: 10.1016/j.jchf.2023.01.021.Peer-Reviewed Original ResearchTrends and Outcomes in Cardiac Arrest Among Heart Failure Admissions
Chouairi F, Miller P, Loriaux D, Katz J, Sen S, Ahmad T, Fudim M. Trends and Outcomes in Cardiac Arrest Among Heart Failure Admissions. The American Journal Of Cardiology 2023, 194: 93-101. PMID: 36889986, DOI: 10.1016/j.amjcard.2023.01.012.Peer-Reviewed Original ResearchConceptsCoronary artery diseaseCardiac arrestHospital cardiac arrestHF admissionsHF hospitalizationArtery diseaseHeart failureRenal diseasePrimary HF admissionsHeart failure admissionsHigher inpatient mortalityClinical Modification codesLong-term outcomesNational Inpatient SampleMultivariate logistic regressionHF patientsInpatient mortalityMultivariate adjustmentInpatient SampleFemale genderTenth RevisionHigher oddsLower oddsInternational ClassificationSerious eventsUse of patient‐reported outcomes in heart failure: from clinical trials to routine practice
Savarese G, Lindenfeld J, Stolfo D, Adams K, Ahmad T, Desai N, Ammirati E, Gottlieb S, Psotka M, Rosano G, Allen L. Use of patient‐reported outcomes in heart failure: from clinical trials to routine practice. European Journal Of Heart Failure 2023, 25: 139-151. PMID: 36644876, DOI: 10.1002/ejhf.2778.Peer-Reviewed Original ResearchConceptsPatient-reported outcomesHeart failureHF careApplication of PROsClinical practiceDisease statusMortality/morbidityPatient-centered approachQuality of lifeDaily clinical routinePerception of diseasePhysician assessmentClinical trialsTraditional careComplex syndromeOwn carePatient experiencePatient's lifeRoutine practiceSymptom severityClinical routineModalities of usePatient's standpointCareTrialsWhen the Whole Is the Sum of Its Parts: Validation of the Heart Failure Collaboratory Medication Composite Score in Denmark
Ahmad F, Ahmad T, Allen L. When the Whole Is the Sum of Its Parts: Validation of the Heart Failure Collaboratory Medication Composite Score in Denmark. Circulation Heart Failure 2023, 16: e010309. PMID: 36695188, PMCID: PMC9974734, DOI: 10.1161/circheartfailure.122.010309.Peer-Reviewed Original ResearchConceptsComposite score
2022
Clinical implications of Type 2 diabetes on outcomes after cardiac transplantation
Chouairi F, Mullan C, Ahmed A, Bhinder J, Guha A, Miller P, Jastreboff A, Fuery M, Chiravuri M, Geirsson A, Desai N, Maulion C, Sen S, Ahmad T, Anwer M. Clinical implications of Type 2 diabetes on outcomes after cardiac transplantation. PLOS ONE 2022, 17: e0273111. PMID: 36516178, PMCID: PMC9750001, DOI: 10.1371/journal.pone.0273111.Peer-Reviewed Original ResearchConceptsPost-transplant mortalityType 2 diabetesAllocation system changeOld allocation systemsHeart transplant recipientsOutcomes of patientsOrgan Sharing databaseProportion of patientsHeart transplantation outcomesLower likelihoodLikelihood of transplantationHigher likelihoodNew allocation systemCardiac transplantationHeart transplantationTransplant recipientsT2D patientsHeart failureSharing databaseCox regressionTransplantation outcomesUnited NetworkWorse outcomesT2DPatientsPragmatic trial of messaging to providers about treatment of acute heart failure: The PROMPT-AHF trial
Ghazi L, O'Connor K, Yamamoto Y, Fuery M, Sen S, Samsky M, Riello R, Huang J, Olufade T, McDermott J, Inzucchi S, Velazquez E, Wilson F, Desai N, Ahmad T. Pragmatic trial of messaging to providers about treatment of acute heart failure: The PROMPT-AHF trial. American Heart Journal 2022, 257: 111-119. PMID: 36493842, DOI: 10.1016/j.ahj.2022.12.002.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyAcute heart failureHeart failurePragmatic trialElectronic health recordsSubstantial health care costsBest practice advisoryReduced ejection fractionUsual care armHealth recordsTime of dischargeEvidence-based careHealth care costsClinical decision support systemAHF patientsCare armEligible patientsHF hospitalizationInpatient initiationCardiovascular deathMedication classesEjection fractionMedical therapyPrimary outcomePractice advisoryNetwork Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction
Park D, An S, Attanasio S, Jolly N, Malhotra S, Doukky R, Samsky M, Sen S, Ahmad T, Nanna M, Vij A. Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction. The American Journal Of Cardiology 2022, 187: 84-92. PMID: 36459752, PMCID: PMC10958453, DOI: 10.1016/j.amjcard.2022.10.026.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBayes TheoremDeathHeart FailureHumansHypotensionNeprilysinNetwork Meta-AnalysisRandomized Controlled Trials as TopicReceptors, AngiotensinStroke VolumeTreatment OutcomeVentricular Dysfunction, LeftConceptsAngiotensin receptor neprilysin inhibitorAngiotensin receptor blockersReduced ejection fractionHeart failureEjection fractionHigh riskCause mortalityReceptor blockersCardiac deathLower riskEnzyme inhibitorsMajor adverse cardiac eventsAngiotensin converting enzyme (ACE) inhibitorsAdverse cardiac eventsEfficacy end pointNetwork meta-analysis approachImproved clinical outcomesRandomized clinical trialsP scoreCardiac eventsAngiotensin receptorsClinical outcomesNeprilysin inhibitorClinical benefitRecent trialsFunctional and Symptomatic Clinical Trial Endpoints The HFC-ARC Scientific Expert Panel
Psotka M, Abraham W, Fiuzat M, Filippatos G, Lindenfeld J, Ahmad T, Felker G, Jacob R, Kitzman D, Leifer E, Lewis E, Mentz R, Nkulikiyinka R, Ni W, Schaber D, Sharma A, Solomon S, Stockbridge N, Teerlink J, Unger E, Whellan D, Wittes J, Anker S, O'Connor C. Functional and Symptomatic Clinical Trial Endpoints The HFC-ARC Scientific Expert Panel. JACC Heart Failure 2022, 10: 889-901. PMID: 36456063, DOI: 10.1016/j.jchf.2022.09.012.Peer-Reviewed Original ResearchConceptsAcademic Research ConsortiumHeart failureSubmaximal exercise tolerancePatient-reported outcomesCardiovascular clinical researchResearch ConsortiumExercise toleranceScientific Expert PanelPatients' qualityFunctional statusClinical trialsLife endpointsConsensus recommendationsClinical utilityDrug AdministrationCardiovascular therapeuticsClinical researchU.S. FoodExpert panelPotential endpointsNational InstituteEvidence generationTrialsEndpointAcademic investigatorsSurvival After Heart Transplantation From SARS-CoV-2–Positive Donors
Mullan CW, Komlo C, Clark KAA, Sen S, Anwer M, Geirsson A, Ahmad T, Davis RP. Survival After Heart Transplantation From SARS-CoV-2–Positive Donors. JACC Heart Failure 2022, 10: 874-876. PMID: 36328657, PMCID: PMC9555312, DOI: 10.1016/j.jchf.2022.08.006.Peer-Reviewed Original ResearchWearables in Cardiovascular Disease
Kumar S, Victoria-Castro AM, Melchinger H, O’Connor K, Psotka M, Desai NR, Ahmad T, Wilson FP. Wearables in Cardiovascular Disease. Journal Of Cardiovascular Translational Research 2022, 16: 557-568. PMID: 36085432, DOI: 10.1007/s12265-022-10314-0.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAlerting Clinicians to 1-Year Mortality Risk in Patients Hospitalized With Heart Failure
Ahmad T, Desai NR, Yamamoto Y, Biswas A, Ghazi L, Martin M, Simonov M, Dhar R, Hsiao A, Kashyap N, Allen L, Velazquez EJ, Wilson FP. Alerting Clinicians to 1-Year Mortality Risk in Patients Hospitalized With Heart Failure. JAMA Cardiology 2022, 7: 905-912. PMID: 35947362, PMCID: PMC9366654, DOI: 10.1001/jamacardio.2022.2496.Peer-Reviewed Original ResearchConceptsUsual care groupElectronic health recordsHeart failureAlert groupMedian agePrimary outcomeFemale patientsTerminal pro-brain natriuretic peptide levelsYale New Haven Health SystemPro-brain natriuretic peptide levelsMedian NT-proBNP levelLeft ventricular ejection fractionLarge tertiary care centerHeart failure hospitalizationHeart failure medicationsNatriuretic peptide levelsNT-proBNP levelsHealth recordsHours of admissionTertiary care centerVentricular ejection fractionRate of hospitalizationIntensive care unitEthnicity groupsSmall community hospitalSGLT2 Inhibitors Should Be Considered for All Patients With Heart Failure ∗
Ahmad T, Desai NR, Velazquez EJ. SGLT2 Inhibitors Should Be Considered for All Patients With Heart Failure ∗. Journal Of The American College Of Cardiology 2022, 80: 1311-1313. PMID: 36041913, DOI: 10.1016/j.jacc.2022.08.005.Peer-Reviewed Original ResearchMachine learning to define phenotypes and outcomes of patients hospitalized for heart failure with preserved ejection fraction: Findings from ASCEND-HF
Murray EM, Greene SJ, Rao VN, Sun JL, Alhanti BA, Blumer V, Butler J, Ahmad T, Mentz RJ. Machine learning to define phenotypes and outcomes of patients hospitalized for heart failure with preserved ejection fraction: Findings from ASCEND-HF. American Heart Journal 2022, 254: 112-121. PMID: 36007566, DOI: 10.1016/j.ahj.2022.08.009.Peer-Reviewed Original ResearchConceptsASCEND-HF trialAtrial fibrillationBlood pressureEjection fractionHeart failureLatent class analysisOutcomes of patientsLong-term outcomesYoung menFour-hour urine outputDistinct phenotypesAcute HFRenal impairmentClinical profileUrine outputASCEND-HFClinical benefitHeterogenous diseaseClinical dataOlder womenHFpEFPatientsOlder individualsCluster 3Asian womenA Clinical Framework for Evaluating Machine Learning Studies ∗
Ghazi L, Ahmad T, Wilson FP. A Clinical Framework for Evaluating Machine Learning Studies ∗. JACC Heart Failure 2022, 10: 648-650. PMID: 35963817, DOI: 10.1016/j.jchf.2022.07.002.Commentaries, Editorials and LettersRationale and design of a pragmatic trial aimed at improving treatment of hyperlipidemia in outpatients with very high risk atherosclerotic cardiovascular disease: A pragmatic trial of messaging to providers about treatment of hyperlipidemia (PROMPT-LIPID)
Shah NN, Ghazi L, Yamamoto Y, Martin M, Simonov M, Riello RJ, Faridi KF, Ahmad T, Wilson FP, Desai NR. Rationale and design of a pragmatic trial aimed at improving treatment of hyperlipidemia in outpatients with very high risk atherosclerotic cardiovascular disease: A pragmatic trial of messaging to providers about treatment of hyperlipidemia (PROMPT-LIPID). American Heart Journal 2022, 253: 76-85. PMID: 35841944, PMCID: PMC9936562, DOI: 10.1016/j.ahj.2022.07.002.Peer-Reviewed Original ResearchConceptsLipid-lowering therapyAtherosclerotic cardiovascular diseaseTreatment of hyperlipidemiaProportion of patientsElectronic health recordsPragmatic trialHigh riskCardiovascular diseaseProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsHigh-risk atherosclerotic cardiovascular diseaseSubtilisin/kexin type 9 inhibitorsLow-density lipoprotein cholesterol reductionImportant public health implicationsEnrollment of patientsPublic health implicationsUsual careSecondary outcomesPrimary outcomeGuideline recommendationsCholesterol reductionPatientsLDLHyperlipidemiaScalable interventionsOutpatientsPragmatic randomized trial assessing the impact of digital health technology on quality of life in patients with heart failure: Design, rationale and implementation
Victoria‐Castro A, Martin M, Yamamoto Y, Ahmad T, Arora T, Calderon F, Desai N, Gerber B, Lee KA, Jacoby D, Melchinger H, Nguyen A, Shaw M, Simonov M, Williams A, Weinstein J, Wilson FP. Pragmatic randomized trial assessing the impact of digital health technology on quality of life in patients with heart failure: Design, rationale and implementation. Clinical Cardiology 2022, 45: 839-849. PMID: 35822275, PMCID: PMC9346973, DOI: 10.1002/clc.23848.Peer-Reviewed Original ResearchConceptsQuality of lifeHF patientsYale New Haven Health SystemKansas City Cardiomyopathy QuestionnaireDigital health technologiesHeart failure careHealth technologiesDigital health interventionsDisease exacerbationHF clinicUsual carePrimary outcomeClinical outcomesHeart failurePatient engagementPatientsHealth interventionsDigital health toolsPatient empowermentHealth systemPatient usabilityHealth toolsEarly detectionFirst enrollmentHealthcare systemThirty-Day and 90-Day Episode of Care Spending Following Heart Failure Hospitalization Among Medicare Beneficiaries
Reinhardt SW, Clark KAA, Xin X, Parzynski CS, Riello R, Sarocco P, Ahmad T, Desai NR. Thirty-Day and 90-Day Episode of Care Spending Following Heart Failure Hospitalization Among Medicare Beneficiaries. Circulation Cardiovascular Quality And Outcomes 2022, 15: e008069. PMID: 35861780, DOI: 10.1161/circoutcomes.121.008069.Peer-Reviewed Original ResearchConceptsHypertensive heart diseaseIndex hospitalizationMedicare beneficiariesPost-acute care spendingService administrative claims dataMedicare Bundled PaymentsHeart failure admissionsHeart failure hospitalizationPrimary discharge diagnosisChronic kidney diseaseAdministrative claims dataCare spendingPostacute care spendingSkilled nursing facilitiesCare Improvement ProgramDrivers of costDiastolic HFHF careHF hospitalizationSystolic HFFailure hospitalizationDischarge diagnosisKidney diseaseObservation staysPostacute careMedicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure
Faridi K, Dayoub E, Ross J, Dhruva S, Ahmad T, Desai N. Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure. Journal Of The American College Of Cardiology 2022, 79: 2516-2525. PMID: 35738713, DOI: 10.1016/j.jacc.2022.04.031.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsAngiotensin receptor neprilysin inhibitorQuadruple therapyOOP costsMedicare coveragePocket costsAngiotensin-converting enzyme inhibitorPrior authorizationAngiotensin receptor blockersQuadruple drug therapyCotransporter 2 inhibitorsMineralocorticoid receptor antagonistsReduced ejection fractionDrug plansReceptor blockersEjection fractionHeart failureDrug therapyReceptor antagonistPrescription drug plansMedicare patientsEnzyme inhibitorsTherapyRegimensMedication prices